Cisplatin–Gemcitabine Treatment Protocol for Bladder Cancer

The gemcitabine–cisplatin regimen is a first-line chemotherapy protocol used particularly to treat muscle-invasive or metastatic bladder cancer. It may be given as neoadjuvant treatment (before surgery) or with palliative intent in metastatic disease.

Gemcitabine

• Gemcitabine (2’,2’-difluorodeoxycytidine) is an antimetabolite chemotherapy agent in the pyrimidine nucleoside analogue class. After entering the cell, it is phosphorylated into its active metabolites, difluorodeoxycytidine triphosphate (dFdCTP) and difluorodeoxycytidine diphosphate (dFdCDP).
• During DNA synthesis, dFdCTP replaces natural deoxycytidine, becomes incorporated into the DNA strand, and halts chain elongation. This inhibits DNA replication, causing cell-cycle arrest in the S phase and triggering apoptosis.
• dFdCDP inhibits the enzyme ribonucleotide reductase, reducing the pool of deoxyribonucleotides that the cell needs for DNA synthesis. This substantially reduces the cell's capacity to replicate.
• This dual action of gemcitabine both directly interferes with DNA synthesis and suppresses nucleotide biosynthesis, increasing cytotoxicity.

Cisplatin

• Cisplatin acts as a platinum-containing alkylating agent. After it enters the cell, chloride ions are replaced by water molecules, activating the drug. Activated cisplatin forms covalent bonds with guanine bases in DNA, particularly at the N7 position.
• These bonds result in intrastrand (within the same strand) and interstrand (between opposing strands) DNA crosslinks.
• These crosslinks disrupt the DNA helix, stall replication and transcription, and activate DNA damage response pathways (for example, through p53).
• If the cell cannot repair this damage, it undergoes programmed cell death (apoptosis).
• Cisplatin is particularly toxic to rapidly dividing cells; however, it is more effective in tumor cells with impaired DNA repair mechanisms.

These two agents suppress tumor cell proliferation and trigger cell death through different but complementary mechanisms. Their combination may produce a synergistic effect and is therefore widely preferred in rapidly proliferating solid tumors such as bladder cancer.

Goals of Treatment

Gemcitabine and cisplatin are given together to shrink bladder tumors and reduce symptoms caused by bladder cancer.

This treatment may be given:

• After surgery, to eliminate microscopic cancer cells that remain,
• Before surgery, to shrink the bladder tumor and reduce the extent of the operation required.
• If there is no metastatic disease (meaning the cancer is confined to the bladder and has not spread elsewhere in the body), gemcitabine and cisplatin are generally given with curative intent (complete recovery).
• If metastatic disease is present (meaning the cancer has spread from the bladder to other parts of the body), this treatment is generally not given with curative intent. Instead, it is used to shrink tumors, reduce symptoms caused by bladder cancer, and extend life.

Treatment Indications

Muscle-Invasive Bladder Cancer

Neoadjuvant treatment (before surgery):

• To reduce tumor size and stage before radical cystectomy.
• To improve the effectiveness of surgery and target micrometastatic disease.
• The goal is a cure.
• Adjuvant treatment (after surgery) (less common): May be given in the presence of positive lymph nodes or high-risk pathology.

Metastatic or Locally Advanced Urothelial Bladder Cancer

• Given as first-line treatment for advanced or disseminated disease.
• Particularly suitable for patients with good performance status and adequate renal function.
• The goals are to reduce tumor burden, control symptoms, and extend life.
• It may also be used in selected cases of non-urothelial subtypes.

Treatment Eligibility Criteria

Renal Function

• The glomerular filtration rate (GFR) must be ≥ 60 mL/min.
• Cisplatin is nephrotoxic; inadequate kidney function can lead to serious damage.
• Carboplatin is preferred in patients with low GFR.

Performance Status

• The ECOG performance score should be 0–1.
• This score indicates the patient's ability to carry out activities of daily living.
• Patients with poorer performance status cannot tolerate treatment.

Hematologic Status

• Adequate bone marrow reserve is required.
• Absolute neutrophil count ≥ 1500/mm³
• Platelets ≥ 100,000/mm³
• Hemoglobin > 9 g/dL
• These are important because of the risk of myelosuppression.

Good Liver Function

• Transaminases (AST/ALT) < 2.5 x ULN
• Bilirubin < 1.5 x ULN
• Gemcitabine is metabolized in the liver.

Good General Systemic Health

Serious comorbidities (heart failure, uncontrolled diabetes, active infection, etc.) must be absent.

Hearing status (optional)

Cisplatin may be ototoxic. Pre-existing hearing loss increases the risk.

Ability to Receive Hydration and Supportive Treatment

Intensive IV fluid support is required before and after cisplatin administration. The patient must be able to tolerate this support.

Conditions That Make Treatment Unsuitable (Contraindications)

• GFR < 60 mL/min (because of the risk of nephrotoxicity)
• ECOG ≥ 2 (poor performance status)
• Severe hearing loss (risk of ototoxicity)
• Active infection or severe comorbidities
• Liver or bone marrow failure

Gemcitabine + Carboplatin: A less toxic alternative for patients with limited kidney function, older patients, or those who are frail.

SGK Reimbursement Status

In Turkey, cisplatin–gemcitabine combination treatment is routinely reimbursed by the Social Security Institution (SGK).

Dosage

Gemcitabine: 1000–1250 mg/m²IV infusion on days 1 and 8

Cisplatin: 70–75 mg/m² (single dose) IV infusion on day 1

Cycle Length: 21 days

Total Number of Cycles: Usually 4 to 6 cycles (determined by the patient's response and tolerability)

Duration of Treatment: Approximately 3 to 4.5 months

Premedication:

Premedication for Cisplatin

• Antiemetic Prophylaxis (High Emetogenic Risk) : A 5-HT₃ receptor antagonist (e.g., ondansetron or granisetron), dexamethasone (8–20 mg IV), and an NK1 receptor antagonist (e.g., aprepitant or fosaprepitant), preferably as a 3-drug antiemetic combination
• Hydration and Renal Protection: Before treatment: 1–2 L of IV fluid (usually 0.9% NaCl), with potassium and magnesium supplementation if needed. After treatment: another 1–2 L of fluid (to ensure adequate urine output). If a diuretic is required: low-dose furosemide.

Premedication for Gemcitabine

• Specific premedication is generally not required, but if there is a history of an allergic or hypersensitivity reaction: an antihistamine (e.g., diphenhydramine) or a corticosteroid (e.g., dexamethasone).
• In older patients or those with previous hematologic toxicity, low-dose G-CSF (filgrastim) support may be planned for neutropenia (given when needed rather than prophylactically).

Conditions Requiring Attention

Close Monitoring of Kidney Function

• Cisplatin is nephrotoxic.
• Before treatment and before each cycle, creatinine, GFR, and electrolytes (Mg, K) should be checked.
• If GFR < 60 mL/min, carboplatin should be considered instead of cisplatin.
• Intensive fluid support should be provided before and after treatment.

Hematologic Toxicities (Myelosuppression)

• Gemcitabine may particularly cause neutropenia and thrombocytopenia.
• A complete blood count should be checked before each cycle.
• If neutrophils are < 1500/mm³ or platelets are < 100,000/mm³, treatment may be delayed or the dose reduced.
• G-CSF (filgrastim) support may be given if needed.

Gastrointestinal Toxicity (Nausea and Vomiting)

• Cisplatin is highly emetogenic.
• Effective antiemetic prophylaxis (a 5HT₃ antagonist + dexamethasone ± an NK1 antagonist) should be given.
• Severe vomiting may disrupt fluid and electrolyte balance.

Ototoxicity

• Cisplatin may have a toxic effect on the auditory nerve.
• Tinnitus and reduced hearing may develop, particularly in older patients.
• Audiometry may be needed before and during treatment.

Peripheral Neuropathy

• Long-term cisplatin use may cause peripheral nerve damage.
• Symptoms such as numbness and tingling in the hands and feet should be monitored.
• If significant neuropathy develops, cisplatin should be discontinued or its dose reduced.

Liver Dysfunction

• Gemcitabine is metabolized by the liver.
• AST/ALT and bilirubin levels should be checked before treatment.
• Dose adjustment may be needed if levels are elevated.

Risk of Infection

• Febrile neutropenia may develop as a result of neutropenia.
• If fever develops, the patient should be assessed immediately and antibiotic treatment started.
• G-CSF support may be needed.

Performance Status and General Health

• The risk of toxicity is high in patients with ECOG ≥2, those who are frail, or those who are very old.
• Alternative protocols (such as gemcitabine + carboplatin) should be considered.

Side Effects

In multidrug treatment, each medicine has its own adverse effects. When these medicines are given together, drug-related adverse effects reported in clinical studies provide the best estimate of the problems likely to occur. The most commonly reported adverse effects of the gemcitabine–cisplatin combination in clinical studies are listed below:

• Nausea and vomiting (75%)
• Low white blood cell count (leukopenia) (35%)
• Low platelet count (thrombocytopenia) (31%)
• Kidney damage (26%)
• Tingling or numbness in the fingers and toes (7%)
• Hearing loss (7%)
• Low red blood cell count (anemia) (20%)
• Diarrhea (15%)
• Infection (11%)
• Inflammation of the mouth (mucositis) (4%)